Reference health

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

15/15 checkable references clean · checked 2026-07-31

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

The 15 checked references that resolve

resolves10.1016/S0140-6736(98)07019-6

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

resolves10.1056/NEJMoa0806470

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

resolves10.2337/dc15-ti01

In This Issue of <i>Diabetes Care</i>

resolves10.1056/NEJMoa072761

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

resolves10.1016/S0140-6736(14)60794-7

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

resolves10.1172/JCI30076

The role of gut hormones in glucose homeostasis

resolves10.1056/NEJMoa1307684

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

resolves10.1056/NEJMoa1305889

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

resolves10.1016/S2213-8587(15)00044-3

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

resolves10.1016/j.clinthera.2014.10.009

Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?

resolves10.1016/j.ahj.2013.09.003

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease

resolves10.1111/j.0006-341X.2000.00779.x

Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests

resolves10.1056/NEJMp1314078

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

resolves10.1016/S0140-6736(14)62225-X

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

resolves10.1111/dom.12441

Regional, age and sex differences in baseline characteristics of patients enrolled in the <scp>T</scp> rial <scp>E</scp> valuating <scp>C</scp> ardiovascular <scp>O</scp> utcomes with <scp>S</scp> itagliptin ( <scp>TECOS</scp> )

What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-31 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

view as graph · paper page

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1056/nejmoa1501352"><img src="https://citestamp.com/citestamped/10.1056/nejmoa1501352/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>

[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1056/nejmoa1501352/badge.svg)](https://citestamp.com/citestamped/10.1056/nejmoa1501352)